Breaking News
June 17, 2018 - Sunovion Announces FDA Acceptance of New Drug Application for Apomorphine Sublingual Film (APL-130277)
June 17, 2018 - Bid to beat obesity focuses on fat that keeps us warm
June 17, 2018 - Work Stress May Increase Risk of Developing Atrial Fibrillation
June 17, 2018 - New Zealand’s secret recipe for active school travel: The neighborhood built environment
June 17, 2018 - New Medscape report reveals sexual harassment rate of physicians
June 17, 2018 - Surgical Blood Transfusions Tied to Clot Risk
June 17, 2018 - CDC chief makes $375K, far exceeding his predecessors’ pay
June 17, 2018 - Education linked to higher risk of short-sightedness
June 17, 2018 - Patients with Moderate-to-Severe Ulcerative Colitis Achieved Clinical and Endoscopic Remission with Mirikizumab in Phase 2 Trial
June 17, 2018 - UA registers a more customised multifocal lens to correct presbyopia
June 17, 2018 - U.S. FDA and European Medicines Agency Accept Regulatory Submissions for Review of Talazoparib for Metastatic Breast Cancer Patients with an Inherited BRCA Mutation
June 17, 2018 - Vaginal estrogen tablets, moisturizers and placebo gel all can improve vaginal discomfort
June 17, 2018 - Addition of Bezafibrate Beneficial in Primary Biliary Cholangitis
June 17, 2018 - Radiation Therapy for Cancer – National Cancer Institute
June 17, 2018 - Technology could help pregnant women detect health complications
June 17, 2018 - Study finds drop in frequent use of ED after Affordable Care Act
June 17, 2018 - Do Antipsychotic Meds for Kids Raise Diabetes Risk?
June 17, 2018 - New light shed on mechanisms of paediatric epilepsy
June 17, 2018 - People who deeply grasp the pain or happiness of others also process music differently in the brain
June 16, 2018 - Scientists discover how cancer-targeting ‘Natural Killer’ cells are fueled in the body
June 16, 2018 - New England Journal of Medicine Publishes Pivotal Cemiplimab Trials Showing Positive Results in Advanced Cutaneous Squamous Cell Carcinoma
June 16, 2018 - Annual Report to the Nation: overall cancer mortality continues to decline, prostate cancer mortality has stabilized
June 16, 2018 - Ibuprofen, acetaminophen more effective than opioids in treating dental pain
June 16, 2018 - Intra-Cellular Therapies Initiates Rolling Submission of New Drug Application for Lumateperone for Treatment of Schizophrenia
June 16, 2018 - Price competition for generic drugs linked to increase in manufacturing-related recalls
June 16, 2018 - Researchers develop biomimetic nanosystem to deliver therapeutic proteins to target tumors
June 16, 2018 - Negative Pressure Wound Tx No Benefit for Lower Limb Open Fx
June 16, 2018 - Should I Get Screened for Prostate Cancer?
June 16, 2018 - Biochemist, physicist team to see antibacterial TCS deform mitochondria
June 16, 2018 - New 2D Superresolution mode for ZEISS Airyscan offers higher resolution in live cell imaging
June 16, 2018 - Money Spurs Those With Heart Disease to Step Lively
June 16, 2018 - Lower Dose of Prostate Cancer Drug with Food
June 16, 2018 - New findings demonstrate how the food we eat affects biochemical signals in the gut
June 16, 2018 - Scientists develop method to determine metabolic activity of neural networks
June 16, 2018 - Topical gel may lower breast cancer risk in women with dense breast tissue
June 16, 2018 - Research team diagnoses asthma with nasal brush test
June 16, 2018 - Dacomitinib Shows More than Seven-Month Improvement in Overall Survival Compared to an Established Therapy in Advanced NSCLC with EGFR-Activating Mutations
June 16, 2018 - Novel PET imaging noninvasively pinpoints colitis inflammation
June 16, 2018 - New clinical trial of MS drug will be first to recognize needs of wheelchair users
June 16, 2018 - Evoke Announces FDA Submission of New Drug Application for Gimoti
June 16, 2018 - New study links gray hair with immune system activity and viral infection
June 16, 2018 - Various E-cigarette flavorings may increase risk of cardiovascular disease
June 16, 2018 - Research sheds light on pathways involved in transmitting itch sensations from skin to brain
June 16, 2018 - Eminent biologist resigns over allegations of gender discrimination and sexual harassment
June 16, 2018 - Consuming sugary soft drinks can make you fat
June 16, 2018 - CDC: Preterm Births Increased in United States During 2014-2016
June 16, 2018 - Adolescents with hay fever have higher rates of anxiety and depression, lower resistance to stress
June 16, 2018 - Metabolic process providing energy to heart muscle fails to mature in babies with hypertrophy
June 16, 2018 - TU Graz researchers manipulate enzymes to build ring-shaped molecular structures
June 16, 2018 - Looking Good! Plastic Surgery for Men Surges
June 16, 2018 - Discovery of how HIV hedges its bets opens the door to new therapies
June 15, 2018 - Researchers evaluate left ventricular systolic function after pulmonary valve replacement
June 15, 2018 - New resource launched based on first-hand experiences of premature baby loss
June 15, 2018 - About Teen Pregnancy | Teen Pregnancy | Reproductive Health
June 15, 2018 - In southern Mozambique, one out of three people diagnosed with HIV do not disclose their status
June 15, 2018 - Researchers discover genomic characteristics that define testicular germ cell cancer
June 15, 2018 - Engineers create first 3D computer model to show breast duct development
June 15, 2018 - ANU scientists invent new system that could help crack down on illegal drug trade
June 15, 2018 - Study shows remarkable plasticity of the brain in finding work-arounds after catastrophic injuries
June 15, 2018 - Study finds higher response to anti-PD1 immunotherapy in older melanoma patients
June 15, 2018 - New Data from Phase 1 Study of Ivosidenib or Enasidenib in Combination with Azacitidine Demonstrate Robust Responses and a Well Tolerated Safety Profile in Newly Diagnosed IDHm AML Patients
June 15, 2018 - Smoking, lack of exercise linked to early death after divorce
June 15, 2018 - Researchers identify gene enhancer that affects sex determination
June 15, 2018 - New collaboration integrates Intabio’s Blaze solution with Bruker’s mass spectrometers
June 15, 2018 - Blood samples can be used to uncover genetic secrets inside the brain
June 15, 2018 - Palatin Technologies Announces FDA Acceptance for Review of Bremelanotide NDA
June 15, 2018 - Can you rely on the drugs that your doctor prescribes?
June 15, 2018 - WHO: Paraguay achieves malaria-free status
June 15, 2018 - Investigating Enamel Nanostructure with Nanoindentation
June 15, 2018 - FDA Approves Moxidectin for the Treatment of River Blindness
June 15, 2018 - Researchers discover cell structure that plays a role in epigenetic inheritance
June 15, 2018 - Study shows how using service dogs may provide physiological benefits to veterans with PTSD
June 15, 2018 - New chemical solution could reduce chances of infection associated with root canal work
June 15, 2018 - Fat and carb rich foods preferred by the brain
June 15, 2018 - Scientists discover unique feature in the ‘antennae’ of light-sensing neurons
June 15, 2018 - Researchers observe increase in activity of neurons grown on single layer of graphene
June 15, 2018 - Researchers find enzyme responsible for aircraft noise-related vascular damage
June 15, 2018 - Study shows improvements in adherence, outcomes of gout patients receiving text message reminders
June 15, 2018 - Accelerated brain maturation linked to stress in childhood
June 15, 2018 - FDA Alert: Compounded Products Containing Triamcinolone-Moxifloxacin by Guardian Pharmacy Services (Dallas, Texas): Alert to Health Professionals
Esketamine Nasal Spray Eases Depression Quickly

Esketamine Nasal Spray Eases Depression Quickly

image_pdfDownload PDFimage_print

Action Points

  • Note that this small randomized trial demonstrated that an intranasal formulation of the s-enantiomer of ketamine had strong anti-depressant effects compared to placebo.
  • Be aware that individuals with psychotic symptoms or a history of psychosis were excluded as the drug could potentiate these symptoms.

An intranasal formulation of ketamine quickly diminished depressive symptoms in patients with treatment-resistant depression, researchers found.

In a phase II study, those taking one of three doses of esketamine (28 mg, 56 mg, or 84 mg) had significantly greater improvement in Montgomery-Asberg Depression Rating Scale (MADRS) scores compared with placebo over 8 days, Ella Daly, MD, of Janssen, and colleagues reported online in JAMA Psychiatry.

Those improvements persisted despite reduced dosing frequency in a subsequent open-label phase that lasted about two months, the researchers said.

Several studies have shown ketamine to have antidepressant effects, and there’s been growing interest in this and other NMDA receptor antagonists, in the class of glutamate receptor modulators, to treat depression and suicidality — especially since about a third of patients don’t respond to current treatment options.

A limitation of ketamine, however, is that it needs to be delivered intravenously. So researchers at Janssen developed an intranasal formulation called esketamine, which is the S-enantiomer of ketamine. This version has a higher affinity for the NMDA receptor than the ketamine R-enantiomer, the researchers explained, adding that nasal delivery will also boost bioavailability of the compound. (The chirally pure molecule can also be patented separately from the racemic form.)

The current study enrolled patients at multiple outpatient referral centers from January 2014 to September 2015. It involved four phases: screening; double-blind treatment (days 1-15) composed of two one-week periods; optional open-label treatment (days 15-74); and post-treatment follow-up (8 weeks).

This design allowed for a smaller sample size to assess efficacy, dose-response, and safety than a standard parallel-group design, while preserving a low chance of type 2 error to avoid missing the efficacy signal, the researchers said.

A total of 67 patients (mean age 45) were randomized, and 60 completed both double-blind periods. All had treatment-resistant depression, which was defined as a lack of clinically meaningful improvement after treatment with at least two different oral antidepressants taken at adequate doses. All of them continued to take their oral antidepressants during the study, and esketamine nasal spray was delivered under the supervision of a healthcare professional.

In the first period, participants were randomized to placebo or to one of the three doses of esketamine. In the second phase, 28 placebo-treated patients with moderate-to-severe symptoms were re-randomized to one of the four treatment arms, while those with mild symptoms continued to receive placebo. Finally, during the open-label phase, dosing frequency was reduced from twice weekly to weekly, then to every two weeks.

The primary efficacy endpoint was change from baseline to 8 days on the MADRS scale.

Overall, Daly and colleagues found that the anti-depressant effect was rapid in onset, evident as early as two hours post-dose, and was dose-related. Mean MADRS scores fell in all groups, with significantly greater improvement in all esketamine dose groups compared with placebo, as well as a dose-response relationship.

  • 28 mg: −4.2, P=0.02
  • 56 mg: −6.3, P=0.001
  • 84 mg: −9.0, P<0.001

These improvements persisted over 8 weeks of follow-up without additional esketamine doses in those who remained in the study, the researchers added. Responses “appeared to persist for more than two months with a lower dosing frequency,” they wrote.

During the double-blind phase, the most common treatment-emergent adverse events in esketamine-treated patients were dizziness, headache, and dissociative symptoms. (The latter has been a problem with racemic ketamine; the quasi-hallucinatory effect has made it a drug of abuse, with street names such as Special K.)

Three of 56 esketamine-treated patients discontinued the study during the blinded phase, as did one of 57 patients during the open-label phase. These included one event each of syncope, headache, dissociative syndrome, and ectopic pregnancy. None of the placebo-treated patients discontinued.

Most esketamine-treated patients had transient elevations in blood pressure and heart rate on dosing days, which returned to normal within two hours of the dose. Perceptual changes or dissociative symptoms began shortly after the start of intranasal dosing, peaked at 30 to 40 minutes, and similarly resolved by two hours. These effects attenuated in all dose groups with repeated dosing, and there was no psychosis.

Daly and colleagues concluded that the results support further investigation in larger trials, and the drug is currently being evaluated in phase III trials in treatment-resistant depression and for patients with major depressive disorder who are at immediate risk for suicide.

In an accompanying editorial, Ole Andreassen, MD, PhD, of Oslo University, and colleagues said the significant effects at just one week are “substantially faster than current treatments.”

While esketamine is a good candidate for intranasal delivery, they wrote, some potential barriers include mucosal inflammation, nasal polyps, and septal deviation. Poor self-administration practices can also reduce efficacy, they noted.

Although there was no psychosis in the trial, patients with psychotic disorders or major depressive disorder with psychosis were excluded, Andreassen and colleagues cautioned. They also urged that “the potential for addiction” be evaluated in future studies.

Still, they said the results demonstrate “considerable promise of combining a compound with rapid antidepressant effects with intranasal delivery” and await results from phase III results.

Several authors are employees of Janssen, which funded the study.

The editorialists disclosed financial relationships with Lundbeck and being co-inventors on an intranasal oxytocin delivery device.

  • Reviewed by
    F. Perry Wilson, MD, MSCE Assistant Professor, Section of Nephrology, Yale School of Medicine and Dorothy Caputo, MA, BSN, RN, Nurse Planner

2017-12-28T16:30:00-0500

Tagged with:

About author

Related Articles